-
Leerink: Treasury Notice Lowers Pfizer-Allergan Deal Chances, Ownership Test Changes A 'Surprise'
Tuesday, April 5, 2016 - 8:49am | 324Read More...The U.S. Treasury’s latest move reduced the benefits of a deal between Pfizer Inc. (NYSE: PFE) and Allergan plc Ordinary Shares (NYSE: AGN), while limiting the number of corporate tax inversions. Leerink’s Jason M. Gerberry noted that Pfizer’s break-up fee is now significantly...
-
Leerink Analysts Hike Shire Outlook, See Next Big Blockbuster Coming
Tuesday, November 17, 2015 - 10:08am | 332Read More...Shares of Shire PLC (ADR) (NASDAQ: SHPG) have been volatile in 2015 and are down 2.6 percent year-to-date. Leerink’s Jason M. Gerberry upgraded the rating on the company from Market Perform to Outperform, while raising the price target from $220 to $239. Recent pullback, positive...
-
Teva Pharmaceutical's Biggest Blockbuster Might Be To Treat Huntington's
Tuesday, September 22, 2015 - 10:59am | 271Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) shares are up 5 percent year-to-date, while hitting a high of $72 on July 23. Leerink’s Jason M. Gerberry maintained an Outperform rating on the company, with a price target of $83. Specialists have indicated blockbuster...
